PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non–Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin Therapy ...

Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered ...

The Working Group agreed on a recommended list of preanalytical minimum technical data elements, clinical context data elements, and patient context data elements for cfDNA-based CSF liquid biopsy in ...

PURPOSECannabis use has experienced partial legalization with a substantial rise over the past decades in the United States. The aim of this study was to evaluate the relationship between cannabis use ...

Postsurgical pain is common among people who undergo breast cancer (BC) surgery and affects health-related quality of life. The aim of this systematic review was to determine the efficacy of ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes ...

Under-reporting of treatment-related adverse events is commonplace in cancer drug trials, which are often accompanied by terms that downplay the seriousness of these events. 1 - 3 Cardiovascular ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Pharmacologic suppression of graft-versus-host disease (GVHD) is critical to the success of hematopoietic stem cell transplantation (HSCT). 1 The use of cyclophosphamide for GVHD prevention has ...

Although innovation in cancer treatment has improved cure rates and survival, the costs have escalated beyond societies' ability to pay. Cancer care costs in the United States are expected to rise to ...

Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's ...